1989
Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions
Elsworth J, Deutch A, Redmond D, Taylor J, Sladek J, Roth R. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions. Neuroscience 1989, 33: 323-331. PMID: 2622529, DOI: 10.1016/0306-4522(89)90212-1.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsParkinson's diseaseStriatal regionsHomovanillic acid/dopamine ratioGross motor abnormalitiesDepletion of dopamineHomovanillic acid levelsLoss of dopamineIdiopathic Parkinson's diseaseCaudate nucleus dopamineAsymptomatic monkeysTetrahydropyridine (MPTP) treatmentAsymptomatic groupSymptomatic groupDopamine lossTetrahydropyridine (MPTP) toxicityMotor abnormalitiesDopamine ratioCaudate nucleusSignificant negative correlationVentromedial regionStriatum
1987
Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF. Brain Research 1987, 415: 293-299. PMID: 3496938, DOI: 10.1016/0006-8993(87)90211-3.Peer-Reviewed Original ResearchConceptsHVA/dopamineVentral tegmental areaMPTP treatmentHomovanillic acidTegmental areaDorsal ventral tegmental areaMesolimbic DA systemCSF homovanillic acidAfrican green monkeysHVA concentrationsNigrostriatal damageMesolimbic systemTetrahydropyridine (MPTP) administrationDA lossNE concentrationCaudate nucleusNucleus accumbensParkinson's diseaseStriatal regionsPrimate brainBaseline levelsVentral partMotor disabilityMPTPGreen monkeys